ArriVent BioPharma (AVBP) Change in Cash (2023 - 2026)

ArriVent BioPharma has disclosed Change in Cash across 4 years of filings, most recently posting $16.6 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $16.6 million, up 167.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.2 million (up 104.57% YoY), and the FY2025 annual result was -$28.8 million, up 62.21% from the prior year.
• Change in Cash came in at $16.6 million for Q1 2026 at ArriVent BioPharma, up from -$67.1 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $167.0 million in Q1 2024 to a low of -$208.6 million in Q4 2024.
• The 4-year median for Change in Cash is -$15.8 million (2024), against an average of -$7.8 million.
• Peak annual rise in Change in Cash reached 494.57% in 2024, while the deepest fall reached 2409.66% in 2024.
• ArriVent BioPharma's Change in Cash stood at $9.0 million in 2023, then tumbled by 2409.66% to -$208.6 million in 2024, then surged by 67.81% to -$67.1 million in 2025, then jumped by 124.67% to $16.6 million in 2026.
• The last three Change in Cash figures came in at $16.6 million (Q1 2026), -$67.1 million (Q4 2025), and -$93000.0 (Q3 2025), per Business Quant data.